文献速递心外重症与机械循环支持

VA-ECMO联合临时机械循环支持治疗心源性休克的时序趋势

Temporal trends in venoarterial extracorporeal membrane oxygenation and concurrent mechanical circulatory support for cardiogenic shock.
PubMed 文献 · J Heart Lung Transplant · 2026-09-11

基于心源性休克工作组登记处11,386例患者,1,502例(13.2%)接受VA-ECMO,其中759例(50.5%)联用临时机械循环支持。联用Impella 5.5与较低住院死亡率相关(aOR 0.62,95%CI 0.45-0.86;p=0.004),而Impella CP或IABP无显著差异。总体死亡率48.4%,急性心梗患者高于心衰休克患者(58.7% vs 40.9%;p<0.001)。

要点

  • VA-ECMO患者中50.5%联用临时机械循环支持,Impella 5.5与较低死亡率相关。
  • 微轴流泵使用从32.2%增至40.2%,IABP从22.8%降至10.9%。
  • 急性心梗休克死亡率58.7%,高于心衰休克40.9%。

核心结论

  • 超过半数VA-ECMO患者联用临时机械循环支持,微轴流泵使用增加而IABP使用下降。
  • 联用Impella 5.5与较低住院死亡率独立相关,而Impella CP或IABP未见显著差异。

研究设计与样本

  • 基于心源性休克工作组登记处的回顾性队列分析,共纳入11,386例心源性休克患者,其中1,502例(13.2%)接受VA-ECMO。
  • 患者分为VA-ECMO单独组或按首个联用装置分组:Impella CP、Impella 5.5或IABP;主要结局为住院死亡率,采用多变量logistic回归评估关联。

主要发现

  • 759例(50.5%)VA-ECMO患者联用临时机械循环支持:Impella CP 321例(21.4%)、Impella 5.5 208例(13.8%)、IABP 230例(15.3%)。
  • 联用Impella 5.5与VA-ECMO单独相比死亡率较低(aOR 0.62,95%CI 0.45-0.86;p=0.004);Impella CP或IABP无显著差异。
  • 总体死亡率为48.4%,急性心梗相关休克死亡率58.7%,高于心衰休克40.9%(p<0.001)。
  • 登记处版本(2021-2025)间,单独VA-ECMO使用稳定(45.0-48.9%;趋势p=0.950),微轴流泵使用增加(32.2%至40.2%;p=0.005),IABP使用下降(22.8%至10.9%;p<0.001)。
  • 缺氧性脑损伤与死亡率关联最强(aOR 10.51,95%CI 6.26-17.64;p<0.001)。

临床怎么用

  • 在心源性休克患者选择VA-ECMO联合装置时,可考虑Impella 5.5与较低死亡率相关,但需结合休克病因和并发症风险个体化决策。
  • 急性心梗相关休克患者死亡率较高,应加强监护和并发症防治,尤其关注缺氧性脑损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is often combined with other temporary mechanical circulatory support (tMCS) in cardiogenic shock, yet combination-specific outcomes remain poorly defined. We compared temporal trends, mortality, complications, and device sequencing across VA-ECMO strategies. METHODS: VA-ECMO patients in the Cardiogenic Shock Working Group registry were analyzed. Patients were grouped as VA-ECMO alone or by first overlapping device: Impella CP, Impella 5.5, or intra-aortic balloon pump (IABP). The primary outcome was in-hospital mortality. Multivariable logistic regression assessed associations with mortality. RESULTS: Of 11,386 cardiogenic shock patients, 1,502 (13.2%) received VA-ECMO, of whom 759 (50.5%) had concurrent tMCS [321 (21.4%) Impella CP, 208 (13.8%) Impella 5.5, and 230 (15.3%) IABP]. Concurrent Impella 5.5 was associated with lower mortality compared to VA-ECMO alone (aOR 0.62, 95% CI 0.45-0.86; p = 0.004); no significant difference was observed for Impella CP or IABP. Overall mortality was 48.4%, higher with acute myocardial infarction (AMI) than heart failure shock (58.7% vs 40.9%; p < 0.001). Across registry versions (2021-2025), isolated VA-ECMO use remained stable over time (45.0-48.9%; p for trend = 0.950), microaxial flow pump use increased (32.2% to 40.2%; p = 0.005), and IABP use declined (22.8% to 10.9%; p < 0.001). Anoxic brain injury was most strongly associated with mortality (aOR 10.51, 95% CI 6.26-17.64; p < 0.001). CONCLUSION: More than half of VA-ECMO patients received a concurrent device, with increasing microaxial flow pump and declining IABP use. Complications and mortality differed across strategies and shock etiologies.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Said C, Sundermeyer J, Hernandez-Montfort J, et al. Temporal trends in venoarterial extracorporeal membrane oxygenation and concurrent mechanical circulatory support for cardiogenic shock. J Heart Lung Transplant. 2026. PMID: 42727718. doi:10.1016/j.healun.2026.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。